Efgartigimod
Primary Immune Thrombocytopenia (ITP)
Key Facts
About Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileAbout Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileAbout Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileAbout Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileAbout Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileTherapeutic Areas
Other Primary Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| HDM1002 (Sovleplenib) | Huadong Medicine (HD Medicine) | NDA Submitted |
| Sovleplenib (HMPL-523) | HUTCHMED | Phase III |
| Orelabrutinib | Zenas BioPharma | Phase 3 |